Mette H Jensen, Lærke S Gasbjerg, Kirsa Skov-Jeppesen, Jens C B Jacobsen, Steen S Poulsen, Cuiqi Zhou, Ruta Jakubauskaite, Frantz R Poulsen, Christian Bonde, Mahmoud Albarazi, Bo Halle, Charlotte B Christiansen, Samra J Sanni, Sarah Byberg, Bjørn Hoe, Jens J Holst, Flemming Dela, Aase K Rasmussen, Filip K Knop, Mai C Arlien-Søborg, Shlomo Melmed, Jens Otto L Jørgensen, Marianne S Andersen, Bolette Hartmann, Marianne C Klose, Ulla Feldt-Rasmussen, Alexander H Sparre-Ulrich, Mette M Rosenkilde
The Journal of Clinical Endocrinology & Metabolism, Volume 110, Issue 3, March 2025, Pages 715–729
https://doi.org/10.1210/clinem/dgae583
About 30% of patients with active acromegaly experience paradoxically increased growth hormone (GH) secretion during the diagnostic oral glucose tolerance test (OGTT). Endogenous glucose-dependent insulinotropic polypeptide (GIP) is implicated in this paradoxical secretion.
We used the GIP receptor (GIPR) antagonist GIP(3–30)NH2 to test the hypothesis that GIP mediates this paradoxical response when GIPR is abundantly expressed in somatotropinomas.
A total of 25 treatment-naive patients with acromegaly were enrolled. Each patient underwent one OGTT during simultaneous placebo infusion and one OGTT during a GIP(3–30)NH2 infusion. Blood samples were drawn at baseline and regularly after infusions to measure GH. We assessed pituitary adenoma size by magnetic resonance imaging and GIPR expression by immunohistochemistry on resected somatotropinomas. For mechanistic confirmation, we applied in vitro and ex vivo approaches. The main outcome measure was the effect of GIP(3–30)NH2 on paradoxical GH secretion during OGTT as a measure of GIP involvement.
In 4 of 7 patients with paradoxical GH secretion, GIP(3–30)NH2 infusion completely abolished the paradoxical response (P = .0003). Somatotrophs were available from 3 of 4 of these patients, all showing abundant GIPR expression. Adenoma size did not differ between patients with and without paradoxical GH secretion.
Of 25 patients with acromegaly, 7 had paradoxical GH secretion during OGTT, and pharmaceutical GIPR blockade abolished this secretion in 4. Corresponding somatotroph adenomas abundantly expressed GIPR, suggesting a therapeutic target in this subpopulation of patients. In vitro and ex vivo analyses confirmed the role of GIP and the effects of the antagonist.
We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.
Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.
